- BioMarin achieved double-digit year-over-year revenue growth with total revenues growing 16% in Q2 2025 and 15% in the first half of 2025 compared to 2024.
- Enzyme Therapies revenue rose 15% year-over-year to $555 million, with PALYNZIQ and VIMIZIM showing strong growth of 20% and 21% respectively.
- Non-GAAP diluted EPS was $1.44 in Q2, increasing more than 3x the rate of revenue growth, with full year guidance raised to $4.40-$4.55.
- Non-GAAP operating margin expanded significantly in Q2 and full year 2025 guidance for operating margin was raised to 33%-34%.
- Non-GAAP R&D expenses decreased compared to Q2 2024 due to focused investment in prioritized assets.
- Non-GAAP SG&A expenses increased due to ERP system implementation and strategic initiatives.
- Operating cash flow reached $185 million in Q2, a 55% increase versus Q2 2024.
- ROCTAVIAN revenue was $9 million in Q2, led by the U.S. and Italy.
- VOXZOGO revenue increased 20% year-over-year to $221 million in Q2, driven by global expansion and new patient starts.
Related items and other data are not available for this feed item.
Dafinchi